Drugs Made In America Acquisition II Corp. DMII
NASDAQ
| 06/30/2026 | 03/31/2026 | 09/30/2025 | 09/30/2025 | ||
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | |
| Total Other Revenue | -- | -- | -- | -- | |
| Total Revenue | -- | -- | -- | -- | |
| Cost of Revenue | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | |
| SG&A Expenses | 194.49% | 72.01% | -- | -- | |
| Depreciation & Amortization | -- | -- | -- | -- | |
| Other Operating Expenses | -- | -- | -- | -- | |
| Total Operating Expenses | 194.49% | 72.01% | -- | -- | |
| Operating Income | -194.49% | -72.01% | -- | -- | |
| Income Before Tax | 11,639.37% | 7,415.01% | -- | -- | |
| Income Tax Expenses | -- | -- | -- | -- | |
| Earnings from Continuing Operations | 11,639.37% | 7,415.01% | -- | -- | |
| Earnings from Discontinued Operations | -- | -- | -- | -- | |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | |
| Minority Interest in Earnings | -- | -- | -- | -- | |
| Net Income | 11,639.37% | 7,415.01% | -- | -- | |
| EBIT | -194.49% | -72.01% | -- | -- | |
| EBITDA | -- | -- | -- | -- | |
| EPS Basic | 2,400.00% | 1,548.94% | -- | -- | |
| Normalized Basic EPS | 2,368.42% | 1,520.00% | -- | -- | |
| EPS Diluted | 2,400.00% | 1,548.94% | -- | -- | |
| Normalized Diluted EPS | 2,368.42% | 1,520.00% | -- | -- | |
| Average Basic Shares Outstanding | 409.60% | 409.60% | -- | -- | |
| Average Diluted Shares Outstanding | 409.60% | 409.60% | -- | -- | |
| Dividend Per Share | -- | -- | -- | -- | |
| Payout Ratio | -- | -- | -- | -- | |